Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

News Releases

Feb 06, 2020

AnPac Bio Gains Two New Insurance Customers

SAN JOSE, Calif. , Feb. 6, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has gained two new

Jan 30, 2020

AnPac Bio Announces Pricing of Initial Public Offering

SAN JOSE, Calif. , Jan. 30, 2020 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has priced its initial

Dec 11, 2019

Anpac Bio Appoints Nobel Prize Winner Dr. Michael Levitt As Chief Consultant To Lead Anpac's Pioneering Efforts In Cancer Screening

SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio" or the "Company") announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio's Innovation and Technical Advisory Board. Dr.

Stock Quote

Change

Volume

52 Week High

52 Week Low

Feb 18, 2020 8:30 PM EST

Events

More events are coming soon.

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information